Research Article
Analysis of Cost Effectiveness of Beta–Lactam Antibiotics in Child Pneumonia Patients
@INPROCEEDINGS{10.4108/eai.14-12-2021.2318538, author={Zainul Islam and Septianita Hastuti and Nadya Firstiana}, title={Analysis of Cost Effectiveness of Beta--Lactam Antibiotics in Child Pneumonia Patients }, proceedings={Proceedings of the 1st International Conference on Economic and Education, ICON 2021, 14 - 15 December 2021, Padang-West Sumatra, Indonesia}, publisher={EAI}, proceedings_a={ICON}, year={2022}, month={7}, keywords={pneumonia; children; antibiotics; cea}, doi={10.4108/eai.14-12-2021.2318538} }- Zainul Islam
Septianita Hastuti
Nadya Firstiana
Year: 2022
Analysis of Cost Effectiveness of Beta–Lactam Antibiotics in Child Pneumonia Patients
ICON
EAI
DOI: 10.4108/eai.14-12-2021.2318538
Abstract
Pneumonia has a high rate of morbidity and mortality. The costs associated with treating pneumonia are high, ranging from 254 to 1,208 USD in Indonesia. The adequate use of antibiotics can help reduce high costs. Pharmacoeconomic studies were conducted to determine the effectiveness of the patients’ treatment costs, one of which was Cost Effectiveness Analysis (CEA), which was used in making decisions on the selection of the best alternative in the selection of treatment costs. This study aims to analyze the most cost-effective antibiotics in pneumonia patients at the Bekasi City General Hospital. This study is descriptive research that uses observation with retrospective data collection and uses the CEA method. Data taken in the form of medical records of pneumonia patients aged 0 months to 5 years. Samples were taken of as many as 100 patients who met the inclusion and exclusion criteria. Based on the results of the ACER value, the effectiveness of the ceftriaxone is higher with a lower cost, compared to cefotaxime with the results of lower effectiveness and higher costs. The ACER results for ceftriaxone cost IDR 39,706/day and cefotaxime IDR 122,571/day. Therefore, it can be concluded that the use of ceftriaxone in pediatric pneumonia was the most cost-effective at Bekasi City General Hospital in 2019-2020.
